CSPC Pharmaceutical Group (DB:CVG) - Cotización, noticias y análisis

Resumen de acción CVG

CSPC Pharmaceutical Group Limited, un holding de inversiones, se dedica a la investigación y desarrollo, fabricación y venta de productos farmacéuticos en la República Popular China, otras regiones asiáticas, Norteamérica, Europa e internacionalmente.

Acerca de la empresa

CVG fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	1/6
Past Performance	2/6
Financial Health	5/6
Dividends	3/6

Recompensas

Cotiza un 36.5% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los beneficios de 4.47%

Cotiza a buen valor en comparación con empresas similares e industria

Análisis de riesgos

El dividendo de 4.22% no está bien cubierto por los flujos de caja

Competidores de CSPC Pharmaceutical Group Limited

Dermapharm Holding

XTRA:DMP

€1.7b

Merck KGaA

XTRA:MRK

€65.3b

PharmaSGP Holding

XTRA:PSG

€268.8m

Pierrel

DB:2FJ0

€92.8m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for CSPC Pharmaceutical Group
Historical stock prices
Current Share Price	HK$0.78
52 Week High	HK$0.91
52 Week Low	HK$0.62
Beta	0.72
1 Month Change	5.68%
3 Month Change	17.46%
1 Year Change	-13.40%
3 Year Change	-22.66%
5 Year Change	-1.54%
Change since IPO	1,406.44%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	CVG	DE Pharmaceuticals	Mercado DE
7D	4.4%	1.5%	-0.5%
1Y	-13.4%	-27.9%	2.5%

Rentabilidad vs. Industria: CVG superó al sector German Pharmaceuticals , que obtuvo un rendimiento del -28.2% el año pasado.

Rentabilidad vs. Mercado: CVG obtuvo unos resultados inferiores a los del mercado German, que fue del 2.3% el año pasado.

Volatilidad de los precios

Is CVG's price volatile compared to industry and market?
CVG volatility
CVG Average Weekly Movement	5.5%
Pharmaceuticals Industry Average Movement	7.2%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	10.3%
10% least volatile stocks in DE Market	2.4%

Precio estable de las acciones: CVG no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de CVG (5%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1992	23,500	Cuilong Zhang	www.cspc.com.hk

CSPC Pharmaceutical Group Limited, un holding de inversiones, se dedica a la investigación y el desarrollo, la fabricación y la venta de productos farmacéuticos en la República Popular China, otras regiones asiáticas, Norteamérica, Europa y a escala internacional. La empresa opera a través de los segmentos de medicamentos acabados, productos a granel y alimentos funcionales y otros. Ofrece cápsulas blandas e inyecciones de NBP para el ictus isquémico agudo; cápsulas e inyecciones de Oulaining para tratar el deterioro mental y de la memoria de leve a moderado; Enxi para tratar la enfermedad de Parkinson idiopática del adulto; Duomeisu para el linfoma, el mieloma múltiple, los cánceres de ovario y mama y otros tumores malignos; Jinyouli para prevenir la leucopenia y la infección inducida por la quimioterapia; y Keaili para el cáncer de mama.

Resumen de fundamentos de CSPC Pharmaceutical Group Limited

¿Cómo se comparan los beneficios e ingresos de CSPC Pharmaceutical Group con su capitalización de mercado?
Estadísticas fundamentales de CVG
Capitalización bursátil	€9.48b
Beneficios(TTM)	€756.29m
Ingresos (TTM)	€4.05b

12.5x

Ratio precio-beneficio (PE)

2.3x

Ratio precio-ventas (PS)

¿Está CVG sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de CVG
Ingresos	CN¥31.45b
Coste de los ingresos	CN¥9.27b
Beneficio bruto	CN¥22.18b
Otros gastos	CN¥16.30b
Beneficios	CN¥5.87b

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	0.50
Margen bruto	70.51%
Margen de beneficio neto	18.68%
Ratio deuda/patrimonio	1.3%

¿Cómo se ha desempeñado CVG a largo plazo?

Ver rendimiento histórico y comparativa

Dividendos

4.1%

Rentabilidad actual por dividendo

51%

Ratio de pagos

¿Paga CVG dividendos fiables?

Ver historial de dividendos e índices de referencia de CVG

¿Cuándo hay que comprar CVG para recibir un próximo dividendo?
fechas de dividendos de CSPC Pharmaceutical Group
Fecha ex dividendo	May 31 2024
Fecha de pago de dividendos	Jun 26 2024
Días hasta ex dividendo	28 days
Días hasta la fecha de pago de dividendos	54 days

¿Paga CVG dividendos fiables?

Ver historial de dividendos e índices de referencia de CVG

Resumen de acción CVG

Recompensas

Análisis de riesgos

Competidores de CSPC Pharmaceutical Group Limited

XTRA:DMP

€1.7b

XTRA:MRK

€65.3b

XTRA:PSG

€268.8m

DB:2FJ0

€92.8m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

CSPC Pharmaceutical Group Limited Proposes Final Dividend for the Year Ended 31 December 2023

CSPC Pharmaceutical Group Limited Announces Highly Selective Mat2A Inhibitor (SYH2039) Obtains Clinical Trial Approval in the U.S

Full year 2023 earnings released: EPS: CN¥0.49 (vs CN¥0.51 in FY 2022)

CSPC Pharmaceutical Group Limited Announces Dapagliflozin Tablets Obtains Drug Registration Approval

Final dividend of HK$0.14 announced

CSPC Pharmaceutical Group Limited, Annual General Meeting, May 28, 2024

Recent updates

CSPC Pharmaceutical Group Limited Proposes Final Dividend for the Year Ended 31 December 2023

CSPC Pharmaceutical Group Limited Announces Highly Selective Mat2A Inhibitor (SYH2039) Obtains Clinical Trial Approval in the U.S

Full year 2023 earnings released: EPS: CN¥0.49 (vs CN¥0.51 in FY 2022)

CSPC Pharmaceutical Group Limited Announces Dapagliflozin Tablets Obtains Drug Registration Approval

Final dividend of HK$0.14 announced

CSPC Pharmaceutical Group Limited, Annual General Meeting, May 28, 2024

Full year 2023 earnings released: EPS: CN¥0.49 (vs CN¥0.51 in FY 2022)

CSPC Pharmaceutical Group Limited Proposes Ordinary Final Cash Dividend for the Year Ended 31 December 2023, Payable on 26 June 2024

CSPC Pharmaceutical Group Limited to Report Fiscal Year 2023 Results on Mar 20, 2024

CSPC Pharmaceutical Group Limited's Bispecific Fusion Protein Drug JMT106 Obtains Clinical Trial Approval from the U.S. Food and Drug Administration

CSPC Pharmaceutical Group Limited Announces Submission of New Drug Application for Irinotecan Liposome Injection to U.S. FDA

CSPC Pharmaceutical Group Limited Obtains Approval for Dextromethorphan Hydrobromide and Quinidine Sulphate Orally Disintegrating Tablets

CSPC Pharmaceutical Group Limited Announces Bivalent Covid-19 MRNA Vaccine (SYS6006.32) Included for Emergency Use in China

Third quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.13 in 3Q 2022)

CSPC Pharmaceutical Group Limited Obtains Approval by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China

CSPC Pharmaceutical Group Limited Obtains Approval by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China

CSPC Pharmaceutical Group Limited to Report Nine Months, 2023 Results on Nov 30, 2023

CSPC Pharmaceutical Group Limited's ALMB-0166 Obtains Approval by the National Medical Products Administration of the People's Republic of China to Conduct Phase II Clinical Trial Evaluating its Efficacy and Safety in Patients with Acute Ischemic Stroke in China

Alphamab Oncology and CSPC Pharmaceutical Group Co., Ltd. Jointly Receive Breakthrough Therapy Designation on KN026 by CDE

CSPC Pharmaceutical Group Limited Obtains Approval Granted by the National Medical Products Administration of the People's Republic of China

CSPC Pharmaceutical Group Limited Obtains Clinical Trial Approval

CSPC Pharmaceutical Group Limited Announces NBL-028 for the Treatment of Advanced Tumors

CSPC Pharmaceutical Group Limited Announces Biologic License Application Approval for Narlumosbart for Injection (JMT103) by the NMPA

Upcoming dividend of HK$0.14 per share at 4.7% yield

CSPC Pharmaceutical Group Limited Announces Semaglutide Injection Obtains Clinical Trial Approval

New major risk - Revenue and earnings growth

CSPC Pharmaceutical Group Limited Obtains Drug Registration Approval Granted by the National Medical Products Administration of the People's Republic of China

CSPC Pharmaceutical Group Limited Declares Interim Dividend for the Six Months Ended 30 June 2023, Payable on 12 October 2023

Second quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.13 in 2Q 2022)

New minor risk - Share price stability

CSPC Pharmaceutical Group Limited to Report First Half, 2023 Results on Aug 23, 2023

Cspc Pharmaceutical Group Limited Announces Biologic License Application of Batoclimab (Hbm9161)

CSPC Ouyi Pharmaceutical Co., Ltd. Obtains Drug Registration Approval Granted by the National Medical Products Administration of the People's Republic of China

CSPC Pharmaceutical Group Limited Obtains Clinical Trial Approval Granted by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China

Cspc Pharmaceutical Group Limited Announces That Clinical Trial Application for Cpo301

Elevation Oncology Inc. Together with CSPC Pharmaceutical Group Limited Announce Promising Initial Clinical Data for SYSA1801 (EO-3021) from the Ongoing Phase 1 Dose Escalation and Expansion Study in China

Elevation Oncology Highlights First-In-Human Phase 1 Sysa1801 (Eo-3021) Clinical Data to Be Presented by Partner Cspc Pharmaceutical Group Limited At Asco 2023

CSPC Pharmaceutical Group Limited Declares Final Dividend for the Year Ended 31 December 2022

Upcoming dividend of HK$0.11 per share at 2.9% yield

First quarter 2023 earnings released: EPS: CN¥0.12 (vs CN¥0.12 in 1Q 2022)

CSPC Pharmaceutical Group Limited to Report Q1, 2023 Results on May 25, 2023

Executive Chairman recently bought €1.5m worth of stock

Full year 2022 earnings released: EPS: CN¥0.51 (vs CN¥0.47 in FY 2021)

CSPC Pharmaceutical Group Limited Announces Highly Selective PRMT5 Inhibitor SYH2045 Obtains Clinical Trial Approval

Cspc Pharmaceutical Group Limited Announces ALMB-0166 for the Treatment of Osteoarthritis Obtains Clinical Trial Approval

CSPC Pharmaceutical Group Limited Receives Approval for SYH2043 from National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China

CSPC Pharmaceutical Group Limited Announces NBL-020 for the Treatment of Advanced Solid Tumors Obtains Clinical Trial Approval in the U.S

Cspc Pharmaceutical Group Limited Announces That Syh2055 Developed by the Group Has Obtained Approval Granted by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China

CSPC Pharmaceutical Group Limited Announces Antibody-Drug Conjugate CPO204 Obtains Clinical Trial Approval in the U.S

Third quarter 2022 earnings released: EPS: CN¥0.13 (vs CN¥0.11 in 3Q 2021)

CSPC Pharmaceutical Group Limited's SYHX1901 Tablets Obtains Approval Granted by the National Medical Products Administration

CSPC Pharmaceutical Group Limited Announces New Indication Application for Marketing Approval of Mingfule

CSPC Pharmaceutical Group Limited to Report Nine Months, 2022 Results on Nov 23, 2022

CSPC Pharmaceutical Group Limited Appoints Li Quan as an Independent Non-Executive Director

Investor sentiment improved over the past week

CSPC Pharmaceutical Group Limited Announces the Antibody-Drug Conjugate Sys6002

CSPC Pharmaceutical Group Limited Announces TG103 Injection Obtains Clinical Trial Approval for the Treatment of Non-Alcoholic Steatohepatitis

Upcoming dividend of HK$0.10 per share

Second quarter 2022 earnings released